Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report)'s stock price traded down 4.8% on Tuesday . The stock traded as low as $30.35 and last traded at $30.51. 607,490 shares changed hands during trading, a decline of 49% from the average session volume of 1,199,263 shares. The stock had previously closed at $32.04.
Analysts Set New Price Targets
A number of research firms recently commented on PCVX. Needham & Company LLC reiterated a "buy" rating and issued a $90.00 target price on shares of Vaxcyte in a report on Tuesday, April 8th. Bank of America cut their price objective on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Guggenheim restated a "buy" rating and issued a $160.00 target price on shares of Vaxcyte in a report on Wednesday, March 12th. The Goldman Sachs Group reduced their target price on Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Finally, Evercore ISI upgraded Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $136.50.
Get Our Latest Analysis on Vaxcyte
Vaxcyte Stock Performance
The stock has a market capitalization of $3.95 billion, a PE ratio of -6.66 and a beta of 1.26. The firm has a 50 day moving average of $60.72 and a 200-day moving average of $83.06.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.16) by $0.14. On average, sell-side analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.
Insider Buying and Selling at Vaxcyte
In related news, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $86.51, for a total transaction of $692,080.00. Following the completion of the sale, the chief financial officer now directly owns 109,491 shares in the company, valued at approximately $9,472,066.41. This trade represents a 6.81 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 32,000 shares of company stock valued at $2,638,800 in the last quarter. Company insiders own 3.10% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of PCVX. Diversified Trust Co bought a new stake in shares of Vaxcyte in the 4th quarter valued at approximately $1,433,000. China Universal Asset Management Co. Ltd. grew its position in Vaxcyte by 23.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 26,428 shares of the company's stock worth $2,163,000 after acquiring an additional 4,962 shares in the last quarter. TimesSquare Capital Management LLC increased its stake in shares of Vaxcyte by 53.7% during the 4th quarter. TimesSquare Capital Management LLC now owns 413,637 shares of the company's stock worth $33,860,000 after purchasing an additional 144,516 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in Vaxcyte by 186.2% in the third quarter. Principal Financial Group Inc. now owns 52,702 shares of the company's stock worth $6,022,000 after purchasing an additional 34,287 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in Vaxcyte by 70.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 593,523 shares of the company's stock worth $49,418,000 after buying an additional 246,049 shares during the last quarter. Hedge funds and other institutional investors own 96.78% of the company's stock.
Vaxcyte Company Profile
(
Get Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Recommended Stories
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
